Results 81 to 90 of about 22,419 (100)

Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis. [PDF]

Korean J Intern Med
Lee BW, Lee JJ, Kim WU.
europepmc   +1 more source

Predictors at diagnosis for start of biologic disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis: a cohort study. [PDF]

BMJ Open
Hameed M, Exarchou S, Eberhard A, Sharma A, Bergström U, Cagnotto G, Einarsson JT, Turesson C.   +7 more
europepmc   +1 more source

Effect of Comedication With Conventional Synthetic Disease‐Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study

, 2016
Alexandre Sepriano, Sofía Ramiro, Désirée van der Heijde, Pedro Ávila-Ribeiro, R. Fonseca, J. Borges, L. Teixeira, P. Carvalho, Marcos Cerqueira, Joana Sousa‐Neves, T. Meirinhos, Anabela Barcelos, Graça Sequeira, Maria João Salvador, J. Canas da Silva, Helena Santos, Miguel Bernardes, Elsa Vieira‐Sousa, Helena Canhão, Jaime Branco, Fernando Pimentel-Santos, Robert Landewé   +21 more
openalex   +1 more source

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

, 2016
Matt Stevenson, Rachel Archer, Jonathan Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Mónica Hernández Alava, Suzy Paisley, Kath Dickinson, David L. Scott, Adam Young, Allan Wailoo   +11 more
openalex   +2 more sources

Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry. [PDF]

Rheumatol Ther
Harigai M, Tanaka E, Inoue E, Sakai R, Sugitani N, Toyoizumi S, Sugiyama N, Yamanaka H.   +7 more
europepmc   +1 more source

The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995-2015). [PDF]

Rheumatol Int
Almutairi KB, Inderjeeth CA, Inderjeeth CA, Preen DB, Keen HI, Nossent JC.   +5 more
europepmc   +1 more source

A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept

, 2016
Vanja Zeremski, Aleksandar Savić, Tatjana Ilić, Ivana Milošević, Marina Maksimovic, Biljana Vučković   +5 more
openalex   +2 more sources

N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs

, 2016
I. G. Kirillova, Д. С. Новикова, Т. В. Попкова, Е Н Александрова, А. А. Новиков, Yu. N. Gorbunova, E. I. Markelova, Yu. O. Korsakova, С. И. Глухова, А. В. Волков, Е. Л. Лучихина, Н. В. Демидова, К. А. Касумова, С А Владимиров, M. A. Kanonirova, GV Lukina, Д. Е. Каратеев, E L Nasonov   +17 more
openalex   +1 more source

Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis. [PDF]

RMD Open
Xie W, Hou Y, Xiao S, Zhang X, Zhang Z.
europepmc   +1 more source

Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, Norway. [PDF]

RMD Open
Tronstad I, Hoff M, Horn J, Vikjord SAA, Videm V, Johansson J, Nilsen TIL, Langhammer A.   +7 more
europepmc   +1 more source